Jing Zhang

List of Publications by Year
in descending order

		1163117	1588992
8	1,178	8	8
papers	citations	h-index	g-index

8	8	8	2947
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling. Cancer Research, 2022, 82, 2097-2109.	0.9	13
2	Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. Nature Communications, 2019, 10, 5177.	12.8	27
3	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018, 361, 290-295.	12.6	134
4	Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell, 2017, 170, 577-592.e10.	28.9	506
5	EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. Oncotarget, 2017, 8, 6787-6795.	1.8	16
6	EglN2 associates with the <scp>NRF</scp>1â€<scp>PGC</scp>1Î± complex and controls mitochondrial function in breastÂcancer. EMBO Journal, 2015, 34, 2953-2970.	7.8	58
7	Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes and Development, 2014, 28, 1429-1444.	5.9	111
8	TRIM32 Protein Modulates Type I Interferon Induction and Cellular Antiviral Response by Targeting MITA/STING Protein for K63-linked Ubiquitination. Journal of Biological Chemistry, 2012, 287, 28646-28655.	3.4	313